诺华制药股价小幅上涨，财报与创新管线成增长引擎

Core Viewpoint - Novartis Pharmaceuticals (NVS.N) has shown a year-to-date stock price increase of 16.36%, outperforming the broader market, despite not reaching historical highs [1]. Stock Performance - The stock opened at $159.60, with a high of $160.70 and a low of $159.47, resulting in a trading range of 0.77%. The pharmaceutical sector overall rose by 0.89% [2]. Financial Performance - For the full year 2025, the company reported revenue of $54.532 billion, reflecting an 8% year-over-year growth, with a core operating profit margin of 40.1%. Key growth drivers include innovative drugs such as Pluvicto and Kisqali. The company anticipates low single-digit growth in net sales for 2026, with a return to high single-digit growth in the second half of the year, and has announced a 6% increase in dividends per share [3]. Strategic Initiatives - The company faces competition from generic drugs for its best-selling products but is investing in innovative pipelines through acquisitions and radioligand therapy. Over the next two years, more than 15 key data readouts are expected. Additionally, an agreement with the U.S. government has been reached to exchange price reductions for tariff exemptions, which helps mitigate business uncertainties [4]. Valuation Metrics - The current price-to-earnings ratio (TTM) stands at 22.44, with a dividend yield of 1.93%. Some institutions are concerned about short-term profit pressures, but the long-term growth narrative remains recognized [5].